Related Experiment Video

Updated: Jul 12, 2026

Analysis of SCAP N-glycosylation and Trafficking in Human Cells
11:27

Analysis of SCAP N-glycosylation and Trafficking in Human Cells

Published on: November 8, 2016

8.8K

SREBP inhibitors: an updated patent review for 2008-present

Zhenyu Peng1, Leyuan Chen2, Manjiang Wang2

  • 1Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Expert Opinion on Therapeutic Patents
|December 6, 2023
PubMed
Abstract

Insights

This patent review highlights Sterol Regulatory Element-Binding Protein (SREBP) inhibitors, crucial for managing diseases linked to lipid metabolism. Several SREBP inhibitors show promise in preclinical studies for various conditions.

Area of Science:

  • Biochemistry and Molecular Biology
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Sterol Regulatory Element-Binding Proteins (SREBP) are transcription factors regulating cholesterol and fatty acid synthesis.
  • Dysregulation of SREBP is implicated in diseases like diabetes, fatty liver disease, and cancer.
  • Developing SREBP inhibitors is a key therapeutic strategy.

Purpose of the Study:

  • To review patents on SREBP inhibitors from 2008 to the present.
  • To analyze the landscape of SREBP inhibitor development.
  • To identify promising SREBP inhibitors for future research.

Main Methods:

  • Comprehensive search of US and European patent databases (USPTO, EPO).
  • Keywords used: 'SREBP' and 'inhibitor'.
  • Analysis of patent data from 2008 to date.

Main Results:

  • Numerous synthetic and natural SREBP inhibitors have been patented.
  • Mechanisms of action for several inhibitors are understood, despite limited structural data.
  • Some SREBP inhibitors demonstrate significant preclinical activity.

Conclusions:

  • SREBP inhibitors represent a growing area of pharmaceutical research.
  • Potential applications in cardio-cerebrovascular diseases and oncology are increasing.
  • Further development of SREBP inhibitors is anticipated due to their therapeutic relevance.
Keywords:
SREBPinhibitorslipidmetabolismtranscription factor

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.0K
Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide07:34

Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide

Published on: May 12, 2023

1.1K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...